- Policy
- Competition in full swing for the ₩100 bil Humira mkt
- by Lee, Tak-Sun Feb 23, 2022 05:50am
- Competition in the domestic Humira biosimilar market is expected to unfold with Celltrion's entry into the market. On how the market that was once dominated by its only biosimilar option, Samsung Bioepis’ Adalloce, will change with the entry of Celltrion in the market, remains the focus of attention. Humira, which is mainly used to treat
- Policy
- Jae-Myung Lee pledges to enact Special Bio Act
- by Lee, Jeong-Hwan Feb 23, 2022 05:49am
- Presidential candidate Jae-Myung Lee of the Democratic Party of Korea announced that he will prepare an appropriate compensation system for domestically developed drugs and new drugs that conduct clinical trials in Korea and enact a ‘Special Act on the Development of the Biohealth Industry’ to foster and develop the Korean bio-health indus
- Policy
- Galvus generics to be reimbursed despite exclusivity period
- by Lee, Tak-Sun Feb 22, 2022 05:55am
- Generic versions of the anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ will be released on the 5th of next month in the marketing exclusivity period that is approved for first generics. This is due to the substance patent period of Galvus that will expire the day before. Therefore, Ahn-gook Pharmaceuticals’ marketing exclusivit
- Policy
- Keytruda to be reimbursed as first-line treatment for NSCLC
- by Lee, Tak-Sun Feb 22, 2022 05:54am
- A new category will be added to reimburse MSD’s NSCLC treatment ‘Keytruda’ as a first-line treatment. This is the first anticancer immunotherapy released in Korea to be reimbursed for NSCLC, five years into its approval as a first-line treatment for non-small-cell lung cancer in Korea. The drug passed deliberations by the Health Insur
- Policy
- Required PMS case reports reduced for Genvoya and Descovy
- by Lee, Hye-Kyung Feb 21, 2022 05:58am
- The number of evidence cases reported for post-marketing surveillance of HIV treatments ‘Genvoya tab (emtricitabine / tenofovir alafenamide/ cobicistat / elvitegravir)’ and ‘Descovy tab (emtricitabine / tenofovir alafenamide) that are subject to reevaluation will be adjusted. Genvoya and Descovy, which received marketing authorization from
- Policy
- Pre-registration of Novavax vaccination will begin
- by Kim, Jung-Ju Feb 21, 2022 05:58am
- The quarantine authorities will start pre-registration of Novavax vaccinations for adults over the age of 18. According to the COVID-19 vaccination promotion team, adults over the age of 18 who want to receive Novavax can make reservations through (http://ncvr.kdca.go.kr). Elderly people who have difficulty making reservations on their own
- Policy
- Tagrisso’s succeeds in RSA renewal… 3% price cut per dose
- by Kim, Jung-Ju Feb 18, 2022 05:55am
- AstraZeneca’s NSCLC treatment Tagrisso (Osimertinib) succeeded in renewing its risk-sharing agreement (RSA) with the National Health Insurance Service, and the price of the drugs will be adjusted and discounted by 3% per dose. According to industry sources, AstraZeneca has agreed to discount the insurance price of Tagrisso during RSA renegot
- Policy
- What is the pledge of the presidential candidates?
- by Lee, Jeong-Hwan Feb 18, 2022 05:54am
- With the 20th presidential election day just 20 days away, candidates from each party completed submitting their teenage pledges with the registration of candidates for the National Selection Commission on the 13th. The main keyword for the health care pledge of Democratic Party of Korea Lee Jae-myung, the power of the people Yoon Seok-yeol,
- Policy
- Rybrevant has been approved in Korea
- by Lee, Tak-Sun Feb 17, 2022 05:52am
- Janssen's Rybrevant, which is conducting a combined clinical trial with Leclaza, a new non-small cell lung cancer treatment drug developed by Yuhan Corporation, has been approved in Korea. The MFDS approved Janssen's Rybrevant on the 15th. This drug is used for "the treatment of patients with local progressive and metastatic non-small cell
- Policy
- Revised the method of Rx notes for health functional foods
- by Lee, Jeong-Hwan Feb 17, 2022 05:52am
- Regarding the regulation of "Note Prescription of Health Functional Foods," the MFDS expressed its position to push for legislation after watching the operation of the prohibited regulation that the health functional food industry voluntarily announced. The government plans to steadily monitor the operation of fair competition rules, draw up
